---
title: Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease.
date: '2024-07-17'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39018531
source: Trending page - PubMed
description: <span class="authors-list-item "><a class="full-name" href="https://pubmed.ncbi.nlm.nih.gov/?term=Peyrin-Biroulet+L&amp;cauthor_id=39018531"
  ref="linksrc=author_name_link" data-ga-category="search" data-ga-action="author_link"
  data-ga-label="Laurent Peyrin-Biroulet">Laurent Peyrin-Biroulet</a><sup class="affiliation-links"><span
  class="author-sup-separator">&nbsp;</span><a class="affiliation-link" title="From
  the Department of Gastroenterology, INFINY Institute, INSERM NGERE, Centre Hospitalier
  Régional Universitaire de Nancy, Vandœuvre-lès-Nancy, France (L.P.-B.); the Division
  of ...
disable_comments: true
---
<span class="authors-list-item "><a class="full-name" href="https://pubmed.ncbi.nlm.nih.gov/?term=Peyrin-Biroulet+L&amp;cauthor_id=39018531" ref="linksrc=author_name_link" data-ga-category="search" data-ga-action="author_link" data-ga-label="Laurent Peyrin-Biroulet">Laurent Peyrin-Biroulet</a><sup class="affiliation-links"><span class="author-sup-separator">&nbsp;</span><a class="affiliation-link" title="From the Department of Gastroenterology, INFINY Institute, INSERM NGERE, Centre Hospitalier Régional Universitaire de Nancy, Vandœuvre-lès-Nancy, France (L.P.-B.); the Division of ...